Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-DOTA-hLL2 Consolidation in Elderly DLBCL
NCT00906841Phase 2Terminated
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Oct 2007
- Primary completion
- Mar 2016
- Countries
- 1
01
Overview
A Phase 2 trial of 90Y-epratuzumab tetraxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by French Innovative Leukemia Organisation. Started Oct 2007; status: terminated.
02
Drugs
90Y-epratuzumab tetraxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00906841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00906841.